96 related articles for article (PubMed ID: 7776831)
1. Evaluation of cAMP involvement in cannabinoid-induced antinociception.
Cook SA; Welch SP; Lichtman AH; Martin BR
Life Sci; 1995; 56(23-24):2049-56. PubMed ID: 7776831
[TBL] [Abstract][Full Text] [Related]
2. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine.
Welch SP; Thomas C; Patrick GS
J Pharmacol Exp Ther; 1995 Jan; 272(1):310-21. PubMed ID: 7815346
[TBL] [Abstract][Full Text] [Related]
3. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
4. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement.
Lichtman AH; Cook SA; Martin BR
J Pharmacol Exp Ther; 1996 Feb; 276(2):585-93. PubMed ID: 8632325
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
6. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.
Houser SJ; Eads M; Embrey JP; Welch SP
Brain Res; 2000 Feb; 857(1-2):337-42. PubMed ID: 10700588
[TBL] [Abstract][Full Text] [Related]
7. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses.
Bonhaus DW; Chang LK; Kwan J; Martin GR
J Pharmacol Exp Ther; 1998 Dec; 287(3):884-8. PubMed ID: 9864268
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
9. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties.
Pertwee RG; Gibson TM; Stevenson LA; Ross RA; Banner WK; Saha B; Razdan RK; Martin BR
Br J Pharmacol; 2000 Apr; 129(8):1577-84. PubMed ID: 10780961
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.
Compton DR; Johnson MR; Melvin LS; Martin BR
J Pharmacol Exp Ther; 1992 Jan; 260(1):201-9. PubMed ID: 1309872
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.
Mason DJ; Lowe J; Welch SP
Eur J Pharmacol; 1999 Aug; 378(3):237-48. PubMed ID: 10493099
[TBL] [Abstract][Full Text] [Related]
12. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice.
Welch SP
J Pharmacol Exp Ther; 1993 May; 265(2):633-40. PubMed ID: 8388455
[TBL] [Abstract][Full Text] [Related]
13. The effects of delta 9-tetrahydrocannabinol and other cannabinoids on cAMP accumulation in synaptosomes.
Little PJ; Martin BR
Life Sci; 1991; 48(12):1133-41. PubMed ID: 1848340
[TBL] [Abstract][Full Text] [Related]
14. XAMI and DCDM, agonists at cAMP-associated octopamine receptors in cockroach nerve cord, produce centrally mediated antinociception in mice.
Raffa RB; Orr N; Connelly CD; Hollingworth RM
Brain Res; 1991 Sep; 559(2):211-9. PubMed ID: 1686573
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.
Viganò D; Rubino T; Vaccani A; Bianchessi S; Marmorato P; Castiglioni C; Parolaro D
Psychopharmacology (Berl); 2005 Nov; 182(4):527-36. PubMed ID: 16079992
[TBL] [Abstract][Full Text] [Related]
16. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism.
Kaminski NE; Koh WS; Yang KH; Lee M; Kessler FK
Biochem Pharmacol; 1994 Nov; 48(10):1899-908. PubMed ID: 7986201
[TBL] [Abstract][Full Text] [Related]
17. Role of cyclic AMP in the actions of cannabinoid receptors.
Childers SR; Deadwyler SA
Biochem Pharmacol; 1996 Sep; 52(6):819-27. PubMed ID: 8781498
[TBL] [Abstract][Full Text] [Related]
18. Dissociable effects of the cannabinoid receptor agonists Δ9-tetrahydrocannabinol and CP55940 on pain-stimulated versus pain-depressed behavior in rats.
Kwilasz AJ; Negus SS
J Pharmacol Exp Ther; 2012 Nov; 343(2):389-400. PubMed ID: 22892341
[TBL] [Abstract][Full Text] [Related]
19. Long-term administration of Delta9-tetrahydrocannabinol desensitizes CB1-, adenosine A1-, and GABAB-mediated inhibition of adenylyl cyclase in mouse cerebellum.
Selley DE; Cassidy MP; Martin BR; Sim-Selley LJ
Mol Pharmacol; 2004 Nov; 66(5):1275-84. PubMed ID: 15286206
[TBL] [Abstract][Full Text] [Related]
20. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats.
Lichtman AH; Dimen KR; Martin BR
Psychopharmacology (Berl); 1995 Jun; 119(3):282-90. PubMed ID: 7675962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
